Factor estimulante de colonias de granulocitos-macrófagos (Galician Wikipedia)

Analysis of information sources in references of the Wikipedia article "Factor estimulante de colonias de granulocitos-macrófagos" in Galician language version.

refsWebsite

Global rank Galician rank

8nih.gov

4^th place

6^th place

7doi.org

2^nd place

7^th place

2web.archive.org

1^st place

1nytimes.com

7^th place

32^nd place

1xconomy.com

low place

1fda.gov

447^th place

749^th place

1centerwatch.com

low place

centerwatch.com

"Newly Approved Drug Therapies (179): Leukine (sargramostim), Immunex". CenterWatch. Arquivado dende o orixinal o 29 de agosto de 2008. Consultado o 2008-10-12.

doi.org

dx.doi.org

Francisco-Cruz A, Aguilar-Santelises M, Ramos-Espinosa O, Mata-Espinosa D, Marquina-Castillo B, Barrios-Payan J, Hernandez-Pando R (2014). "Granulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factor". Med. Oncol. 31 (1): 774. PMID 24264600. doi:10.1007/s12032-013-0774-6.
Voehringer D (2012). "Basophil modulation by cytokine instruction". Eur. J. Immunol. 42 (10): 2544–50. PMID 23042651. doi:10.1002/eji.201142318.
Subramanian Vignesh K, Landero Figueroa JA, Porollo A, Caruso JA, Deepe GS (2013). "Granulocyte macrophage-colony stimulating factor induced Zn sequestration enhances macrophage superoxide and limits intracellular pathogen survival". Immunity 39 (4): 697–710. PMC 3841917. PMID 24138881. doi:10.1016/j.immuni.2013.09.006.
Hansen PJ, Dobbs KB, Denicol AC (2014). "Programming of the preimplantation embryo by the embryokine colony stimulating factor 2". Anim. Reprod. Sci. 149 (1-2): 59–66. PMID 24954585. doi:10.1016/j.anireprosci.2014.05.017.
Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L (2013). "Trial Watch: Immunostimulatory cytokines". Oncoimmunology 2 (7): e24850. PMC 3782010. PMID 24073369. doi:10.4161/onci.24850.
Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH (2011). "Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans". Nature 477 (7362): 99–102. PMID 21886163. doi:10.1038/nature10358.
Deiß A, Brecht I, Haarmann A, Buttmann M (2013). "Treating multiple sclerosis with monoclonal antibodies: a 2013 update". Expert Rev Neurother 13 (3): 313–35. PMID 23448220. doi:10.1586/ern.13.17.

fda.gov

accessdata.fda.gov

"Approval Summary for sargramostim". Oncology Tools. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 1991-03-05. Arquivado dende o orixinal o 24 de xuño de 2007. Consultado o 20 September 2009.

nih.gov

ncbi.nlm.nih.gov

Francisco-Cruz A, Aguilar-Santelises M, Ramos-Espinosa O, Mata-Espinosa D, Marquina-Castillo B, Barrios-Payan J, Hernandez-Pando R (2014). "Granulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factor". Med. Oncol. 31 (1): 774. PMID 24264600. doi:10.1007/s12032-013-0774-6.
Voehringer D (2012). "Basophil modulation by cytokine instruction". Eur. J. Immunol. 42 (10): 2544–50. PMID 23042651. doi:10.1002/eji.201142318.
Subramanian Vignesh K, Landero Figueroa JA, Porollo A, Caruso JA, Deepe GS (2013). "Granulocyte macrophage-colony stimulating factor induced Zn sequestration enhances macrophage superoxide and limits intracellular pathogen survival". Immunity 39 (4): 697–710. PMC 3841917. PMID 24138881. doi:10.1016/j.immuni.2013.09.006.
Hansen PJ, Dobbs KB, Denicol AC (2014). "Programming of the preimplantation embryo by the embryokine colony stimulating factor 2". Anim. Reprod. Sci. 149 (1-2): 59–66. PMID 24954585. doi:10.1016/j.anireprosci.2014.05.017.
"Entrez Gene: CSF2 colony stimulating factor 2 (granulocyte-macrophage)".
Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L (2013). "Trial Watch: Immunostimulatory cytokines". Oncoimmunology 2 (7): e24850. PMC 3782010. PMID 24073369. doi:10.4161/onci.24850.
Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH (2011). "Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans". Nature 477 (7362): 99–102. PMID 21886163. doi:10.1038/nature10358.
Deiß A, Brecht I, Haarmann A, Buttmann M (2013). "Treating multiple sclerosis with monoclonal antibodies: a 2013 update". Expert Rev Neurother 13 (3): 313–35. PMID 23448220. doi:10.1586/ern.13.17.

nytimes.com

Schmeck HM (1987-11-02). "Radiation Team Sent to Brazil Saves Two With a New Drug". New York Times. Consultado o 2012-06-20.

web.archive.org

"Approval Summary for sargramostim". Oncology Tools. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 1991-03-05. Arquivado dende o orixinal o 24 de xuño de 2007. Consultado o 20 September 2009.
"Newly Approved Drug Therapies (179): Leukine (sargramostim), Immunex". CenterWatch. Arquivado dende o orixinal o 29 de agosto de 2008. Consultado o 2008-10-12.

xconomy.com

Stewart Lyman for Xcocomy. June 11, 2010 Biotech Drug Discovery in Seattle: A Look Back